Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Subscribe To Our Newsletter & Stay Updated